pH-Responsive Nano Carriers for Doxorubicin Delivery
- 946 Downloads
The aim of this study was to design stimuli-responsive nanocarriers for anti-cancer drug delivery. For this purpose, doxorubicin (DOX)-loaded, polysebacic anhydride (PSA) based nanocapsules (NC) were combined with pH-sensitive poly (L-histidine) (PLH).
PSA nano-carriers were first loaded with DOX and were coated with poly L-histidine to introduce pH sensitivity. The PLH-coated NCs were then covered with polyethylene glycol (PEG) to reduce macrophage uptake. The drug release profile from this system was examined in two different buffer solutions prepared as acidic (pH5) and physiological (pH 7.4) media. The physical and chemical properties of the nanocapsules were characterized by Fourier transform infrared spectroscopy (FTIR), dynamic light scattering (DLS), ultraviolet and visible absorption spectroscopy (UV–VIS), and scanning electron microscopy (SEM). In vitro studies of the prepared nanocapsules were conducted in MDA-MB-231 breast cancer cells.
The results obtained by SEM and DLS revealed that nanocapsules have spherical morphology with an average size of 230 nm. Prepared pH sensitive nanocapsules exhibited pH-dependent drug release profile and promising intracellular release of drug. PEGylation of nanoparticles significantly prevented macrophage uptake compared to non-PEGylated particles.
KEY WORDSdoxorubicin nanocapsule pH-responsive poly L-histidine polysebacic anhydride
American type culture collection
Dynamic light scattering
Enhanced permeability and retention
Food and drug administration
Fourier transform infrared spectroscopy
Gel permeation chromatography
Proton nuclear magnetic resonance
Phosphate buffered saline
Poly dispersity index
Roswell park memorial institute
Scanning electron microscopy
Ultraviolet and visible absorption spectroscopy
ACKNOWLEDGMENTS AND DISCLOSURES
This research was supported by The Scientific and Technological Research Council of Turkey (TUBITAK) with grant No: 111M385. GG and BN were supported by funding from the Norwegian Cancer Society.
- 17.ImageJ. 2013 December 15. Available from: http://rsb.info.nih.gov/ij [Website].
- 19.Bankar VH, Gaikwad PD, Pawar SP. Novel sustained release drug delivery systems: review. IJPRD. 2011;3(12):1–14.Google Scholar
- 29.Denard B, Lee C, Ye J. Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1. elife Camb. 2012;18(1):e00090.Google Scholar